Monoclonal Anti- CK19 / CYFRA21-1 (Detection Ab) Antibody

Catalog# BDA1012

Lot # Check on the product label

Size 1mg

Isotype IgG1

Clone # C4

Host Mouse

Reactivity Human

Product Form Liquid

Purification & Buffer

Protein A or G purified and supplied in 0.01 M PBS (pH7.4) & 0.15 M NaCl without preservative.

Purity >95% by HPLC & SDS-PAGE

Immunogen 

40 KDa of Keratin 19 protein.

Specificity It specifically recognize the human CK19 / CYFRA21-1, and may cross react with CK20, CK8 & CK18. 

Recommend Application

Western Blot

ELISA

Chemilumineseent immunoassay, CLIA

Other applications have not been tested.

The optimal dilutions should be determined by end user.

Matched antibody pair

Capture Ab: CYFRA21-1 mAb (clone # D5)

Detection Ab: CYFRA21-1 mAb (clone # C4)

Storage Instruction 

Aliquot and store at -20°C for long term (at least one year).

Avoid repeated freeze and thaw cycles.

Background

Keratin, type I cytoskeletal 19 also known as cytokeratin-19 (CK-19) or keratin-19 (K19) is a 40 kDa protein that in humans is encoded by the KRT19 gene. KRT19 is also known as Cyfra 21-1. The usefulness of serum CYFRA 21-1 (cytokeratin-19 fragments) in monitoring the recurrence of breast cancer and in evaluating therapeutic effects. Serum CYFRA 21-1 may be a reliable marker of recurrence or therapeutic efficacy. The serum level of Cyfra21-1 was a useful biomarker for diagnosis of nonsmall cell lung cancer (NSCLC) as well. The serum cytokeratin 19 fragment 21.1 (CYFRA21-1) level was elevated in nasopharyngeal carcinoma (NPC) and can function as a biomarker for detection and monitoring of NPC. After analyzing NPC group and healthy control group, Song XM et al concluded that the serum CYFRA21-1 level could be a reliable and effective biomarker for the detection and monitoring of NPC tumor progression.

Reference

1. Schweizer J, Bowden PE, Coulombe PA, Langbein L, Lane EB, Magin TM, Maltais L, Omary MB, Parry DA, Rogers MA, Wright MW (July 2006). "New consensus nomenclature for mammalian keratins". J Cell Biol 174 (2): 169–74.

2. Nakata B, Takashima T, Ogawa Y, Ishikawa T, Hirakawa K. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer. Br J Cancer. 2004 Aug 31;91(5):873-8.

3. Cui C, Sun X, Zhang J, Han D, Gu J. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis. J Cancer Res Ther. 2014 Nov;10 Suppl:C131-4.

4. Song XM, Wang SZ, Wang ZJ, Cao WJ, L J, Chen F. Serum CYFRA21-1 as an effective tumor biomarker for patients with nasopharyngeal carcinoma. Neoplasma. 2015;62(1):124-9.